ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

MBRX Moleculin Biotech Inc

4.4477
-0.0758 (-1.68%)
Last Updated: 13:32:49
Delayed by 15 minutes
Company Name Stock Ticker Symbol Market Type
Moleculin Biotech Inc MBRX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0758 -1.68% 4.4477 13:32:49
Open Price Low Price High Price Close Price Prev Close
4.59 4.4001 4.59 4.5235
more quote information »

Recent News

Date Time Source Heading
4/18/202408:30PRNUSEuropean Medicines Agency (EMA) Grants Orphan Drug..
4/10/202408:30PRNUSMoleculin Announces Presentation of Positive Data..
3/28/202410:45PRNUSMoleculin to Present at the MedInvest Biotech & Pharma..
3/27/202409:25PRNUSMoleculin to Participate in the Virtual Investor Lunch..
3/27/202409:05PRNUSMoleculin Announces U.S. Patent Issue Notification for..
3/25/202407:30PRNUSMoleculin Announces Positive Interim Data in Annamycin..
3/22/202416:05PRNUSMoleculin Reports Full Year 2023 Financial Results
3/20/202407:30PRNUSMoleculin to Report Full Year 2023 Financial Results on..
3/20/202407:15IHMARKETNEWSJPMorgan boosts dividends, Chipotle unveils 50:1 stock..
3/19/202416:30PRNUSMoleculin Announces Reverse Stock Split
3/12/202409:05PRNUSMoleculin to Present at the 36th Annual ROTH Conference
2/29/202408:30EDGAR2Form 8-K - Current report
2/22/202409:30EDGAR2Form 8-K - Current report
2/16/202417:19EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
2/15/202409:15EDGAR2Form 8-K - Current report
2/14/202416:36EDGAR2Form 8-K - Current report
2/14/202416:33EDGAR2Form 8-K - Current report
2/13/202400:15EDGAR2Form EFFECT - Notice of Effectiveness
2/02/202417:05EDGAR2Form S-1 - General form for registration of securities under..
1/24/202408:50EDGAR2Form 8-K - Current report
1/24/202408:50PRNUSMoleculin Announces 2023 Year-End Annamycin Clinical Trials..
1/16/202417:00EDGAR2Form DEF 14A - Other definitive proxy statements
1/05/202417:15EDGAR2Form PRE 14A - Other preliminary proxy statements
1/05/202417:14EDGAR2Form 8-K - Current report
12/27/202307:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/22/202317:00EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
12/21/202317:17EDGAR2Form 8-K - Current report
12/20/202321:16PRNUSMoleculin Announces Pricing of $4.5 Million Registered..
12/18/202308:55EDGAR2Form 8-K - Current report
12/11/202308:55EDGAR2Form 8-K - Current report
12/11/202308:50EDGAR2Form 8-K - Current report
12/11/202308:50PRNUSMoleculin Presents Positive Interim Data from Phase 1B/2..
11/20/202309:15EDGAR2Form 8-K - Current report
11/13/202308:30EDGAR2Form 8-K - Current report
11/13/202308:05EDGAR2Form 8-K - Current report
11/13/202308:05PRNUSMoleculin Announces Positive Interim Data in Annamycin..
11/13/202308:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/13/202308:00EDGAR2Form 8-K - Current report
11/13/202308:00PRNUSMoleculin Reports Third Quarter 2023 Financial Results
11/07/202308:45EDGAR2Form 8-K - Current report
11/07/202308:45PRNUSMoleculin to Report Third Quarter Financial Results on..
11/06/202308:35EDGAR2Form 8-K - Current report
11/06/202308:35PRNUSMoleculin Presents Positive Preliminary Efficacy Findings..
11/03/202316:30EDGAR2Form 8-K - Current report
10/17/202309:00EDGAR2Form 8-K - Current report
10/11/202309:05PRNUSMoleculin to Participate in the Virtual Investor Ask the CEO..
10/06/202317:15EDGAR2Form 8-K - Current report
10/02/202308:40EDGAR2Form 8-K - Current report
10/02/202308:40PRNUSMoleculin Doses First Subjects in Phase 2 Portion of..
9/21/202308:50EDGAR2Form 8-K - Current report

Your Recent History

Delayed Upgrade Clock